U.S. markets closed
  • S&P Futures

    4,168.25
    -8.00 (-0.19%)
     
  • Dow Futures

    34,028.00
    -53.00 (-0.16%)
     
  • Nasdaq Futures

    13,995.00
    -34.50 (-0.25%)
     
  • Russell 2000 Futures

    2,255.40
    -3.60 (-0.16%)
     
  • Crude Oil

    62.82
    -0.31 (-0.49%)
     
  • Gold

    1,776.20
    -4.00 (-0.22%)
     
  • Silver

    26.00
    -0.10 (-0.40%)
     
  • EUR/USD

    1.1976
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3828
    -0.0012 (-0.09%)
     
  • USD/JPY

    108.7500
    -0.0330 (-0.03%)
     
  • BTC-USD

    56,609.39
    -4,668.66 (-7.62%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
Sol-Gel Technologies Ltd.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NESS ZIONA, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Raymond James Institutional Investors Conference

Speakers:

Dr. Alon Seri-Levy, Chief Executive Officer

Date:

8:20 AM ET on March 1, 2021

Access:

Available to conference participants.

H.C. Wainwright Global Life Sciences Conference

Speakers:

Gilad Mamlok, Chief Financial Officer

Date:

March 9-10, 2021

Access:

Available on demand to conference participants.

A webcast replay of the presentation at H.C. Wainwright Life Sciences Conference will be available in the Investors/Events and Presentations section of the Company’s website at www.sol-gel.com for 30 days.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Michael Levitan
Solebury Trout
+1-646-378-2920
mlevitan@soleburytrout.com

Source: Sol-Gel Technologies Ltd.